Biomarkers: Technological and Commercial Outlook 2013-2023

July 2013 | 178 pages | ID: BB1C13D397EEN
Visiongain

Abstracts

Biomarkers - how to find R&D trends and potential sales

What's the outlook for biomarkers? Visiongain's updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. See what's happening for those technologies, finding how you can gain.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses show you commercial prospects

Besides revenue forecasting, our work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 65 tables, 60 charts, and two interviews.

Is your searching for data on biomarkers a challenging task? Now make it easier. You can stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

Our new study lets you investigate the most promising and lucrative parts of that field - assess technologies and their applications. You hear what's happening and see where the money lies. Try our new report, then, getting a feel for that industry's potential.

The following sections show how you benefit from our investigation.

Prospects for the world biomarkers market and its submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of 11 biomarker submarkets to 2023, starting with main divisions:

• Discovery
• Diagnostics
• Services.

You see, too, world revenues to 2023 divided into technological disciplines:

• Genomics
• Proteomics
• Bioinformatics
• Other applications.

You also find world revenue predictions to 2023 by therapeutic field:

• Cancers
• Cardiovascular diseases
• CNS disorders
• Other illnesses.

How will those markets for biomarkers expand? Which applications will generate most money? You investigate that industry, finding the most promising places for investments and sales.

The study also breaks its overall forecast into geographical regions.

National markets - what outlooks for biomarker demand?

Worldwide progress in pharmaceuticals and diagnostics expand use of biomarkers. Hear about the best revenue prospects for those medical tools.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).

There you discover countries with highest revenues and potential sales growth. Our work explains. You assess that technology's future, seeing progress and finding what it means.

Developments and opportunities affecting biomarkers

Our report shows you issues and events affecting that industry and market from 2013, including these:

• Biomarkers for efficacy and safety of drugs
• Companion diagnostics and personalised medicines
• Imaging biomarkers in clinical trials
• Pharmacogenomics, proteomics, and metabolomics.

That study discusses other aspects of the technology too, including these:

• Funding for biomarker discovery and research
• Validation of biomarkers in oncology
• Mergers and acquisitions (M&A)
• Alliances, partnerships, collaborations, and licensing
• Interest from pharma companies, inc. Pfizer, Novartis, Merck, Sanofi, and Roche.

There you explore political, economic, social, and technological questions, assessing outlooks for business. See, then, what restrains and what helps the biomarkers industry.

You investigate R&D too, finding possibilities for technological and commercial advances. See there what the future holds.

Companies and 2018 market value

What happens next? Our report predicts the world market for biomarker systems will reach $29.25bn in 2018 - with high growth - and expand further to 2023. Find how high revenues can go.

Our work also shows you what technologies and organisations hold greatest potential. See profiles of 25 companies. First you examine contract service providers (CROs), including these:

• Quintiles
• Covance
• Parexel
• Charles River Laboratories
• ICON
• WuXi AppTec.

Next you assess technology providers, including these companies:

• Affymetrix
• Agilent
• QIAGEN
• Life Technologies
• Thermo Fisher Scientific.

Then, for diagnostic testing systems, you examine developers and producers including these:

• Quest Diagnostics
• Myriad Genetics
• Genomic Health
• Critical Diagnostics
• MDxHealth.

There you analyse participants' results, capabilities, and outlooks. You find 210 organisations mentioned. You also read two interviews with leaders in the industry. Discover what authorities think, say, and do, helping you stay ahead.

Information found nowhere else

Biomarkers: Technological and Commercial Outlook 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See how you could benefit your research, analysis, and decisions. Also find how you can save time and get recognition for insight.

Biomarkers for healthcare - assess potentials now, seeing what you can gain

Our new report is for everyone investigating biomarker technologies. There discover revenue forecasts to 2023 at overall world market, submarket, and national level. Find discussions too. Avoid missing out then - please order the report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Biomarkers: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Market Definition, 2013

2. AN INTRODUCTION TO BIOMARKERS

2.1 Definition of a Biomarker
  2.1.1 A Brief History of Biomarkers
  2.1.2 The Importance of Biomarkers
2.2 Biomarker Discovery and Validation
2.3 Uses of Biomarkers
  2.3.1 Assessing Drug Efficacy
  2.3.2 Assessing Drug Safety
  2.3.3 Companion Diagnostics
    2.3.3.1 CLIA vs. FDA Approval
  2.3.4 Therapeutic Importance of Biomarkers
  2.3.5 Imaging Biomarkers
    2.3.5.1 Imaging Biomarkers in Clinical Trials
2.4 Biomarkers and Personalised Medicine
2.5 Biomarker Discovery
  2.5.1 Genomics
    2.5.1.1 Pharmacogenomics
  2.5.2 Proteomics
  2.5.3 Metabolomics

3. THE WORLD BIOMARKERS MARKET, 2013-2023

3.1 The World Biomarkers Market, 2012
  3.1.1 The World Biomarkers Market by Sector, 2012
  3.1.2 The World Biomarkers Market by Discipline, 2012
3.2 The World Biomarkers Market: Overall Revenue Forecast, 2013-2023
  3.2.1 Lack of Investment and Reimbursement Issues May Restrain Market
3.3 The World Biomarker Discovery Submarket, 2012
  3.3.1 The World Biomarker Discovery Submarket: Revenue Forecast 2013-2023
3.4 The World Biomarker Diagnostics Submarket, 2012
  3.4.1 The World Biomarker Diagnostics Submarket: Revenue Forecast, 2013-2023
3.5 The World Biomarker Services Submarket, 2012
  3.5.1 The World Biomarker Services Submarket: Revenue Forecast, 2013-2023
3.6 The World Biomarkers Market: Overall Revenue Forecast by Discipline, 2013-2023
  3.6.1 The Genomics Submarket: Revenue Forecast, 2013-2023
    3.6.1.1 Next Generation Sequencing to Drive Growth
    3.6.1.2 Increased Focus on Genomic Research in China
    3.6.1.3 Application in Cardiovascular Disease
  3.6.2 The Proteomics Submarket: Revenue Forecast, 2013-2023
    3.6.2.1 Advances in Detection Technology Will Drive Market
  3.6.3 The Bioinformatics Submarket: Revenue Forecast, 2013-2023
    3.6.3.1 Market to Gather Pace with New Tools and Software in Pipeline
3.7 Growth in Key Biomarker Disciplines, 2013-2023

4. LEADING INDICATIONS FOR BIOMARKER DISCOVERY AND DEVELOPMENT, 2013-2023

4.1 The World Biomarkers Market by Indication, 2012
4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2013-2023
4.3 Cancer Biomarker Submarket, 2012
  4.3.1 A Brief History of Cancer Biomarker Research
  4.3.2 The Current State of Cancer Biomarker Research
    4.3.2.1 Cancer Genome Atlas
  4.3.3 Many Cancer Diagnostics Are Reaching the Market
  4.3.4 Opportunities and Challenges for Cancer Biomarkers
    4.3.4.1 Prostate Cancer: The Search for Urine Biomarkers
    4.3.4.2 Lung Cancer: High Biomarker Owing to Disease Prevalence
  4.3.5 Cancer Biomarker Submarket: Revenue Forecast, 2013-2023
4.4 Cardiovascular Disease Biomarker Submarket, 2012
  4.4.1 A Brief History of Cardiovascular Biomarker Research
  4.4.2 The Current State of Cardiovascular Disease Biomarker Research
  4.4.3 Cardiovascular Disease Diagnostics
  4.4.4 The Future of Cardiovascular Biomarker Research
  4.4.5 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2013-2023
4.5 CNS Diseases Biomarker Submarket, 2012
  4.5.1 The Current State of CNS Disease Biomarker Research
  4.5.2 Biomarker-Based Diagnostics for CNS Diseases
    4.5.2.1 DiaGenic: Targeting Neurodegenerative Diseases
  4.5.3 Neuroimaging Biomarkers: Limitations in Sensitivity May Restrict Market
  4.5.4 CSF Biomarkers: Biochemical Composition of CSF Offers Potential
  4.5.5 Alzheimer's Disease: Beyond Amyloid Beta
  4.5.6 Multiple Sclerosis: Search for Disease Biomarker
  4.5.7 Parkinson's Disease: Effective Biomarker Yet to be Discovered
    4.5.7.1 Fluid-Based Biomarker Discovery
  4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2013-2023
4.6 Growth in Key Biomarker Indications, 2013-2023

5. LEADING NATIONAL BIOMARKER MARKETS, 2013-2023

5.1 The World Biomarkers Market: Regional Breakdown, 2012
5.2 The World Biomarkers Market: Regional Forecast, 2013-2023
5.3 Strong Base for Biomarker Research in US
  5.3.1 The US Biomarker Market: Revenue Forecast, 2013-2023
5.4 Top 5 EU Biomarker Markets, 2012
  5.4.1 Top 5 EU Biomarker Markets: Revenue Forecasts, 2013-2023
  5.4.2 French Government Funds $17m Cancer Biomarker Effort
    5.4.2.1 France: Biomarker Market Revenue Forecast, 2013-2023
  5.4.3 Focus on Biomarkers Prompts Opening of New Centre in Germany
    5.4.3.1 Germany: Biomarker Market Revenue Forecast, 2013-2023
  5.4.4 UK: Increased Funding for Biomarker Research
    5.4.4.1 The UK Biomarker Market: Revenue Forecast, 2013-2023
  5.4.5 Healthcare Cuts Restricting Drug Development in Spain
    5.4.5.1 Spain: Biomarker Market Revenue Forecast, 2013-2023
  5.4.6 Italy: United Action to Increase Validation of Oncology Biomarkers
    5.4.6.1 Italy: Biomarker Market Revenue Forecast, 2013-2023
5.5 Company Alliances and Partnerships Grow in Japan
  5.5.1 Japan: Biomarker Market Revenue Forecast, 2013-2023
5.6 Expanding Economy Driving Biotechnology in China
  5.6.1 Companies Entering the Chinese Market
  5.6.2 LightArray Biotech
  5.6.3 China: Biomarker Market Revenue Forecast, 2013-2023
5.7 Attractiveness of Drug Development Outsourcing in India
  5.7.1 India: Biomarker Market Revenue Forecast, 2013-2023
5.8 Investment in Local Drug Development to Drive Russian Market
  5.8.1 Russia: Biomarker Market Revenue Forecast, 2013-2023
5.9 Brazil: Diagnostic Cardiac Biomarkers Gains Interest
  5.9.1 Brazil: Biomarker Market Revenue Forecast, 2013-2023

6. BIOMARKER INDUSTRY TRENDS, 2013-2023

6.1 Strengths and Weaknesses of the Biomarkers Market, 2012
6.2 Opportunities and Threats in the Biomarkers Market, 2013-2023
6.3 STEP Analysis of the World Biomarkers Market
6.4 Social Factors
  6.4.1 Patient Stratification: Striving Towards Personalised Medicine
  6.4.2 Biomarker Hype May Not Always Lead to New Discoveries
  6.4.3 Growing Emphasis on Oncology for Companies
6.5 Technological Factors
  6.5.1 Decreasing Size, Increasing Sensitivity
    6.5.1.1 ABT Molecular Imaging
  6.5.2 The Need for More-Efficient Data Storage
6.6 Economic Factors
  6.6.1 Biomarkers: Cutting the Cost of Drug Development
    6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures
  6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups
  6.6.3 Outsourcing Biomarker Discovery and Development
6.7 Political Factors
  6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery
  6.7.2 Improving Regulatory Guidelines to Speed Development
  6.7.3 Concerns over Biomarker Patenting Hits Innovation
6.8 Challenges in Developing Biomarkers
6.9 Combining Drug and Diagnostic Development
6.10 MicroRNA Biomarkers: A Prospective Target?
6.11 Big Pharma and Biomarkers
  6.11.1 Pfizer: Loss of Patent Protection on Key Drug Prompts Search for New Biomarkers
  6.11.2 Novartis: Spotlight on Cancer Biomarkers
  6.11.3 Merck & Co.: Multi-Platform Applications for Company's Biomarkers
  6.11.4 Sanofi: Developing Cancer Companion Diagnostics
  6.11.5 Roche
    6.11.5.1 Roche Diagnostics
    6.11.5.2 Ventana Medical Systems
    6.11.5.3 Roche 454 Life Sciences
  6.11.6 GSK: Using Genomic Technologies to Discover Fibrosis Biomarkers
  6.11.7 AstraZeneca: Speciality Focus Through Dedicated In-House Biomarker Team
  6.11.8 Abbott Laboratories/Abbott Molecular: Licensing Agreements and Acquisitions

7. LEADING COMPANIES IN THE BIOMARKERS MARKET, 2013

7.1 Biomarker Service Providers
  7.1.1 Global CROs and Biomarkers
    7.1.1.1 Not All Global CROs Are Investing in Biomarkers
  7.1.2 Quintiles: Leading Biomarker Developer with Strong Portfolio
  7.1.3 Covance: Specialist Team Prompts Opening of New Biomarker: New Centre
  7.1.4 Parexel: New Direction in Neuronal Biomarkers?
  7.1.5 Charles River Laboratories: In Vitro Biomarker Platforms
  7.1.6 ICON: Offering a Range of Biomarker Activities
  7.1.7 WuXi AppTec: Agreement with QIAGEN Allows Shared Expertise
  7.1.8 Caprion Proteomics: Specialising In Protein Biomarkers
  7.1.9 Proteome Sciences: Sales Surge Due to Biomarker Licensing
  7.1.10 Pacific Biomarkers: Penetrating the Indian Market
  7.1.11 Oxford Gene Technology: Caner and Lupus Biomarkers in Pipeline
  7.1.12 Worldwide Clinical Trials: Dedicated Laboratory in Place for Biomarker Services
7.2 Biomarker Technology Providers
  7.2.1 Affymetrix: Innovative GeneChip Technology Provides Discovery Platform
    7.2.1.1 QuantiGene
  7.2.2 Agilent: Broad Range of Technological Capabilities
    7.2.2.1 Agilent and Diagnostics
    7.2.2.2 Growing Asian Markets: Focus on South Korea
  7.2.3 AB SCIEX: Next Generation Mass Specs to be Launched
  7.2.4 QIAGEN: Strong History in Acquisitions and Licensing Agreements
  7.2.5 Life Technologies: Provider of Next Generation Sequencing Systems
  7.2.6 Axela: Simplifying Biomarker Development
  7.2.7 Thermo Fisher Scientific: BRAHMS Acquisition Leads to Further Licensing Agreements
    7.2.7.1 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre
7.3 Biomarker Diagnostic Developers
  7.3.1 Quest Diagnostics: Celera Acquisition Expands Company Offerings
  7.3.2 Myriad Genetics: Focus on Diagnostic Tests for Genetic Cancer Biomarkers
    7.3.2.1 Pipeline
    7.3.2.2 Myriad RBM
  7.3.3 Genomic Health: Building on the Oncotype Dx Brand
  7.3.4 Critical Diagnostics: Detecting Markers for Cardiovascular Indications
  7.3.5 BG Medicine: Testing for Cardiovascular Disease
  7.3.6 Epigenomics: Discovering Novel Biomarkers Through Company Alliances
    7.3.6.1 Diagnostic Product Portfolio
  7.3.7 MDxHealth: Applying DNA Methylation Techniques in Biomarker Discovery

8. OPINIONS FROM OUR SURVEY: RESEARCH INTERVIEWS

8.1 Dr Thomas Turi, Vice President, Science and Technology, Discovery and Translational Services, Covance
  8.1.1 Evolution of the Biomarker Services Market
  8.1.2 Covance Services and Market Competition
  8.1.3 The Importance of Company Collaborations and Future Prospects
8.2 Dr John L Allinson, Vice President Biomarker Laboratory Services, ICON plc.
  8.2.1 Outlook of the Current Biomarker Market
  8.2.2 Staying Ahead of Competition
  8.2.3 Leading Disease Indications and Market Threats

9. CONCLUSIONS

9.1 State of the World Biomarkers Market in 2012
9.2 Growth in the World Biomarkers Market, 2013-2023
  9.2.1 Dominance of Leading Western Markets
9.3 The Use of Biomarkers in Drug Discovery and Development
9.4 Demand for New Diagnostics

List Of Tables

LIST OF TABLES

Table 1.1 Currency Exchange Rates
Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2012
Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2012
Table 2.3 Technologies and Platforms for Biomarker Research, 2012
Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2012
Table 3.2 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2012
Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2013-2023
Table 3.4 World Biomarkers Market: Market Shares (%) by Sector, 2012-2023
Table 3.5 Biomarker Discovery Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.7 Biomarker Services Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.8 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2013-2023
Table 3.9 Genomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 3.11 Proteomics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.12 Bioinformatics Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 3.13 World Biomarker Market: Market Shares (%) by Discipline, 2012-2023
Table 4.1 World Biomarkers Market: Market Share (%) by Indication, 2012
Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Indication, 2013-2023
Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2012
Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2012
Table 4.5 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2012-2023
Table 4.7 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 4.8 World Biomarkers Market: Market Share (%) by Indication, 2012-2023
Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2012
Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2013-2023
Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2012-2023
Table 5.4 US Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.5 Top 5 EU Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012
Table 5.6 Top Five EU Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2013-2023
Table 5.7 France: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.8 Germany: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.9 UK Biomarker Market: Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.10 Spain: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.11 Italy: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.12 Japan: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.13 China: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.14 India: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.15 Russia: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 5.16 Brazil: Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2013-2023
Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2013-2023
Table 6.2 World Biomarkers Market: Opportunities and Threats, 2013-2023
Table 6.3 World Biomarkers Market: STEP Analysis, 2013-2023
Table 6.4 US Cancer Deaths by Tumour Type, 2012
Table 6.5 Selected Cancer Therapies Approved With a Biomarker, 2011
Table 6.6 PSTC Biomarkers in Development, 2012
Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($bn, AGR %, CAGR %), 2002-2012
Table 6.8 IMI-Funded Biomarker Projects, 2009-2012
Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast ($bn, AGR %, CAGR %), 2012, 2018 & 2023
Table 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012
Table 7.2 Proteome Sciences: Revenue, 2012-2012
Table 7.3 Affymetrix: Revenue by Division, 2010-2012
Table 7.4 Myriad Genetics: Biomarker Product Portfolio, 2012
Table 7.5 Myriad Genetics: Revenue by Product, 2012
Table 7.6 Myriad Genetics: Diagnostic Pipeline, 2012
Table 7.7 Genomic Health: Revenue by Division, 2010-2012
Table 7.8 BG Medicine: Revenue by Division, 2010-2012
Table 7.9 Epigenomics: Revenue and Market Shares by Sector, 2011 & 2012
Table 7.10 MDxHealth: Pipeline, 2012
Table 7.11 MDxHealth: Revenue by Source, 2010-2012
Table 9.1 World Biomarkers Market: Revenues ($bn, CAGR %) by Sector, 2012, 2018 and 2023
Table 9.2 World Biomarkers Market: Revenues ($bn, CAGR %) by Discipline, 2012, 2018 and 2023
Table 9.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease, 2012, 2018 and 2023
Table 9.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Country, 2012, 2018 and 2023

About

Market to Gather Pace with New Tools and Software in Pipeline

Bioinformatics plays a key role in the biomarker discovery process, bridging the gap between initial discovery phases such as experimental design, clinical study execution, and bioanalytics, including sample preparation, separation and high-throughput profiling and independent validation of identified candidate biomarkers. With future technologies capable of generating even greater volumes of data, visiongain believe bioinformatic techniques will continue to be employed widely during the development of biomarkers. Future growth in the bioinformatics market will rely upon the development of tools and software capable of managing the high volumes of data produced by technologies involved in the discovery and development of biomarkers.

Bioinformatic approaches to biomarker discovery are particularly valuable in cancer therapy. Owing to the multifactorial nature of cancer, it is likely that a combination of several markers will be necessary to effectively detect and diagnose malignant tumour growth. For this, in addition to highthroughput genomic or proteomic profiling, sophisticated bioinformatics tools will be needed for the complex analysis of data and pattern recognition.

Other drivers for growth in this submarket include the development of tools for combining data from a variety of sources. Researchers are increasingly looking to combine biomarkers discovered through more than one source, through genomic and proteomic analysis, for example. Using multiple biomarkers allows for a more accurate analysis of disease. However, analysing data created by various instruments is challenging and current bioinformatics tools are not able to cope, visiongain believes. Development of advanced tools will simplify multiple biomarker research.

It is obvious that emerging bioinformatics tools for exploring metabolic pathways and networks, thus allowing for mapping expression profiles of genes or proteins simultaneously onto these pathways, are of high importance for the biological interpretation of biomarkers from a systems biology viewpoint . Such tools thus contribute to a better understanding of how genes, proteins and metabolites act and interact in such networks, and consequently how human diseases manifest themselves.